文献速递肝病

预测原发性胆汁性胆管炎患者对奥贝胆酸应答的评分系统的开发与验证

Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-05-22

研究利用意大利RECAPITULATE队列(N=441)和IBER-PBC队列(N=244)两个真实世界前瞻性队列,开发并外部验证了奥贝胆酸应答评分(ORS)及治疗6个月后的ORS+,用于预测原发性胆汁性胆管炎患者对奥贝胆酸的生化应答概率。ORS内部验证c-statistic为0.75、0.78、0.72,ORS+提升至0.83、0.88、0.81;外部验证ORS为0.70、0.72、0.71,ORS+为0.80、0.84、0.78。

要点

  • ORS基于治疗前年龄、瘙痒、肝硬化、ALP/ULN、ALT/ULN、GGT/ULN和胆红素预测奥贝胆酸应答。
  • ORS+额外纳入治疗6个月后的ALP/ULN和胆红素,内部验证c-statistic最高达0.88。
  • 外部验证中ORS+的c-statistic为0.80、0.84、0.78,轻度和重度疾病组结果一致。

核心结论

  • 开发并外部验证了能按不同标准预测奥贝胆酸应答的评分系统,可增强原发性胆汁性胆管炎分层二线治疗模式。

研究设计与样本

  • 使用意大利RECAPITULATE(N=441)和IBER-PBC(N=244)奥贝胆酸真实世界前瞻性队列数据开发/验证评分。
  • 采用后向选择的多变量Cox回归获得简约预测模型,预测至24个月的生化应答。

主要发现

  • ORS内部验证c-statistic:POISE应答0.75、ALP/ULN<1.67应答0.78、正常范围应答0.72。
  • ORS+内部验证c-statistic:POISE应答0.83、ALP/ULN<1.67应答0.88、正常范围应答0.81。
  • 外部验证ORS的c-statistic:POISE应答0.70、ALP/ULN<1.67应答0.72、正常范围应答0.71。
  • 外部验证ORS+的c-statistic:POISE应答0.80、ALP/ULN<1.67应答0.84、正常范围应答0.78。
  • 轻度和重度疾病组结果一致。

关键数值与推荐

  • ORS包含年龄、瘙痒、肝硬化、ALP/ULN、ALT/ULN、GGT/ULN和胆红素,具体组成取决于应答标准。
  • ORS+还包含奥贝胆酸治疗6个月后的ALP/ULN和胆红素。
  • 预测结局为至24个月按POISE标准(ALP/ULN<1.67且较基线降低至少15%,且胆红素正常)、ALP/ULN<1.67或正常范围标准(ALP、ALT和胆红素均正常)的生化应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Obeticholic acid (OCA) is the only licensed second-line therapy for primary biliary cholangitis (PBC). With novel therapeutics in advanced development, clinical tools are needed to tailor the treatment algorithm. We aimed to derive and externally validate the OCA response score (ORS) for predicting the response probability of individuals with PBC to OCA. METHODS: We used data from the Italian RECAPITULATE (N = 441) and the IBER-PBC (N = 244) OCA real-world prospective cohorts to derive/validate a score including widely available variables obtained either pre-treatment (ORS) or also after 6 months of treatment (ORS+). Multivariable Cox regressions with backward selection were applied to obtain parsimonious predictive models. The predicted outcomes were biochemical response according to POISE (alkaline phosphatase [ALP]/upper limit of normal [ULN]<1.67 with a reduction of at least 15%, and normal bilirubin), or ALP/ULN<1.67, or normal range criteria (NR: normal ALP, alanine aminotransferase [ALT], and bilirubin) up to 24 months. RESULTS: Depending on the response criteria, ORS included age, pruritus, cirrhosis, ALP/ULN, ALT/ULN, GGT/ULN, and bilirubin. ORS+ also included ALP/ULN and bilirubin after 6 months of OCA therapy. Internally validated c-statistics for ORS were 0.75, 0.78, and 0.72 for POISE, ALP/ULN<1.67, and NR response, which raised to 0.83, 0.88, and 0.81 with ORS+, respectively. The respective performances in validation were 0.70, 0.72, and 0.71 for ORS and 0.80, 0.84, and 0.78 for ORS+. Results were consistent across groups with mild/severe disease. CONCLUSIONS: We developed and externally validated a scoring system capable to predict OCA response according to different criteria. This tool will enhance a stratified second-line therapy model to streamline standard care and trial delivery in PBC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. De Vincentis A, Ampuero J, Terracciani F, et al. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2024. PMID: 38782175. doi:10.1016/j.cgh.2024.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。